Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result Meeting Abstract

  

Authors:	Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; Wasserheit-Lieblich, C.; Fontes Santos De Teive Argolo, D.; Baselga, J.; Norton, L.; Hudis, C. A.; Dang, C. T.
Abstract Title:	Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
Meeting Title:	51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	15 Suppl.
Meeting Dates:	2015 May 29-Jun 2
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-05-20
Language:	English
ACCESSION:	WOS:000358036901386
PROVIDER:	wos
DOI:	10.1200/JCO.2015.33.15_suppl.607
Notes:	Meeting Abstract: 607 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80595